Mckesson Corp (MCK) Stock Price & Analysis
Mckesson Corp (MCK) rose 1.99% to USD 840.9 as of July 25, 2026 at 01:13 UTC, according to Nexqual real-time market data.
MCK last closed at USD 824.49; the session ranged USD 827.53–843.53 on volume of 633,281 shares. Market capitalization is —, with a 52-week range of USD 637–999 (NYQ). Source: Nexqual, July 25, 2026 at 01:13 UTC.
Key Statistics (as of July 25, 2026 at 01:13 UTC)
| Price | USD 840.9 |
|---|---|
| Change | ▲ 1.99% (up) |
| Previous Close | USD 824.49 |
| Open | USD 829.93 |
| Day Range | USD 827.53 – 843.53 |
| 52-Week Range | USD 637 – 999 |
| Volume | 633,281 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (MCK)
Nexqual's technical model rates MCK "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 01:13 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 61.87 (neutral) |
| vs SMA50 | Above (USD 778.72) |
| MACD | 15.36 (positive) |
Analyst Ratings (MCK)
Wall Street analysts rate MCK "Strong Buy" based on 15 analysts, with a mean price target of USD 945.47 (range USD 812–1,065), per Nexqual as of July 25, 2026 at 01:13 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 945.47 |
| High Target | USD 1,065 |
| Low Target | USD 812 |
| Buy / Hold / Sell | 15 / 2 / 0 |
Earnings (MCK)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 9.54 |
| Revenue Estimate | $103.74B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 11.69 vs est 11.57 ▲ beat |
| 2025-12-31 | USD 9.34 vs est 9.27 ▲ beat |
| 2025-09-30 | USD 9.86 vs est 9.05 ▲ beat |
| 2025-06-30 | USD 8.26 vs est 8.15 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financials & Fundamentals (MCK)
| Total Revenue | $403.43B |
|---|---|
| Revenue Growth (YoY) | +6.00% |
| Gross Margin | +3.60% |
| Operating Margin | +2.21% |
| Profit Margin | +1.18% |
| Current Ratio | 0.85 |
| Total Cash | $3.98B |
| Total Debt | $8.79B |
| Free Cash Flow | $5.66B |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financial Health Score (MCK)
Nexqual rates Mckesson Corp's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 01:13 UTC.
| Growth | Solid — Revenue +6% YoY (latest Q) |
|---|---|
| Profitability | Weak — Gross margin 4%, operating 2% |
| Balance Sheet | Mixed — $3.98B cash vs $8.79B debt |
| Cash Flow | Mixed — FCF $5.66B, slim 1.4% margin |
| Efficiency | Mixed — No data |
Ownership (MCK)
| Insider Ownership | +0.05% |
|---|---|
| Institutional Ownership | +95.34% |
| Float | 120.02M |
| Short % of Float | +3.52% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Leadership (MCK)
Mckesson Corp is led by Brian S. Tyler (age 58), CEO & Chairman, per Nexqual as of July 25, 2026 at 01:13 UTC.
| CEO & Chairman | Brian S. Tyler (age 58) |
|---|---|
| Executive VP and Chief Strategy & Business Development Officer | Thomas L. Rodgers (age 54) |
| Executive VP & CFO | Kenny K. Cheung (age 43) |
| Executive VP, Chief Information Officer & CTO | Francisco J. Fraga (age 52) |
| Executive VP & Group President of North American Pharmaceutical Services | Kirk Kaminsky |
Major Backers & Investors (MCK)
Notable institutional backers of Mckesson Corp include JPMorgan, FMR, LLC, Franklin Resources, Inc., according to Nexqual as of July 25, 2026 at 01:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 3.79% |
| FMR, LLC | 3.08% |
| Franklin Resources, Inc. | 2.62% |
| Massachusetts Financial Services Co. | 2.48% |
| Morgan Stanley | 1.96% |
| MFS SERIES TRUST I-MFS Value Fund | 1.66% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.21% |
| BlackRock | 11.13% |
| State Street | 6.14% |
| Geode Capital | 2.48% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
From Mckesson Corp's Latest SEC 10-K Filing (filed 2026-05-08)
Key Strengths & Strategy (as disclosed to the SEC)
- Combined with Sarah Cannon Research Institute and our technology business, Ontada, this segment provides research, insights, technologies, and services that address and improve cancer and specialty care.
- During the second quarter of fiscal 2025, we approved enterprise-wide initiatives to modernize and accelerate our technology service operating model, which were intended to improve business continuity, compliance, operating efficiency, and advance investments to streamline the organization.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CAH | Cardinal Health, Inc. | USD 228.03 | ▲ 3.4% |
| HUM | Humana Inc. | USD 389.32 | ▼ 2.08% |
| CI | The Cigna Group | USD 289.57 | ▲ 1.66% |
| HCA | HCA Healthcare, Inc. | USD 382.19 | ▲ 2.78% |
| LH | Labcorp Holdings Inc. | USD 296.77 | ▲ 5.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:13 UTC. This page is informational and not investment advice.